Evaluation of two mineral trioxide aggregate compounds as pulp-capping agents in human teeth.
OBJECTIVE
The present randomized, controlled prospective study evaluated the histomorphological response of human dental pulps capped with two grey mineral trioxide aggregate (MTA) compounds.


METHODS
Pulp exposures were performed on the occlusal floor of 40 human permanent pre-molars. The pulp was capped either with ProRoot (Dentsply) or MTA-Angelus (Angelus) and restored with zinc oxide eugenol cement. After 30 and 60 days, teeth were extracted and processed for histological examination and the effects on the pulp were scored. The data were subjected to Kruskal-Wallis and Conover tests (alpha = 0.05).


RESULTS
In five out of the 40 teeth bacteria were present in pulp tissue. No significant difference was observed between the two materials (P > 0.05) in terms of overall histological features (hard tissue bridge, inflammatory response, giant cells and particles of capping materials). Overall, 94% and 88% of the specimens capped with MTA-Angelus and ProRoot, respectively, showed either total or partial hard tissue bridge formation (P > 0.05).


CONCLUSIONS
Both commercial materials ProRoot (Dentsply) and MTA-Angelus (Angelus) produced similar responses in the pulp when used for pulp capping in intact, caries-free teeth.
Accorinte
M L R
ML
Department of Dental Materials, School of Dentistry, University Brás Cubas, São Paulo, SP, Brazil.
Loguercio
A D
AD
Reis
A
A
Bauer
J R O
JR
Grande
R H M
RH
Murata
S S
SS
Souza
V
V
Holland
R
R
D000328:Adult; D017607:Aluminum Compounds / Q000627:therapeutic use*; D017610:Calcium Compounds / Q000627:therapeutic use*; D003738:Dental Cements / Q000627:therapeutic use*; D003782:Dental Pulp / Q000187:drug effects / Q000382:microbiology; D003785:Dental Pulp Capping; D003789:Dental Pulp Exposure / Q000628:therapy*; D003790:Dental Pulp Necrosis / Q000473:pathology; D003807:Dentin Sensitivity / Q000473:pathology; D003809:Dentin, Secondary / Q000473:pathology; D004338:Drug Combinations; D005500:Follow-Up Studies; D015726:Giant Cells / Q000473:pathology; D006801:Humans; D009804:Odontoblasts / Q000473:pathology; D010087:Oxides / Q000627:therapeutic use*; D011446:Prospective Studies; D011671:Pulpitis / Q000473:pathology; D017640:Silicates / Q000627:therapeutic use*; D016037:Single-Blind Method; D015035:Zinc Oxide-Eugenol Cement / Q000627:therapeutic use
D017607:Aluminum Compounds; D017610:Calcium Compounds; D003738:Dental Cements; D004338:Drug Combinations; D010087:Oxides; D017640:Silicates; D015035:Zinc Oxide-Eugenol Cement; C086631:mineral trioxide aggregate